This study is testing a radiation treatment called Stereotactic Hypofractionated Radioablation (HYDRA) for people with laryngeal cancer (cancer of the voice box). The main goal is to find the highest dose of HYDRA radiation that can be given safely. Researchers will also study how safe this treatment is. You might be able to join if you are over 18, have squamous cell carcinoma of the larynx, and meet other health criteria. The study is currently unclear on its recruitment status and aims to enroll 11 participants.

Study design

This study is an interventional trial with an unclear phase, planning to enroll 11 participants. Participants will be assigned to increasing doses of HYDRA radiation in groups until the highest tolerable dose is found.

What's involved

You would receive HYDRA radiation over about two weeks, for a total of up to 5 times. You will also complete quality of life and symptom questionnaires at several points over at least 6 months.

Compensation

Not stated in the trial record.

Follow-up

You will be followed for at least 6 months after your last dose of HYDRA, with follow-up visits every 3 months for the first 2 years, and then every 6 months after that.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.